Crossmark

Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcR- and ACE2-positive cells

Crossref DOI link: https://doi.org/10.1038/s41598-022-19993-w

Published Online: 2022-09-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shimizu, Jun

Sasaki, Tadahiro

Koketsu, Ritsuko

Morita, Ryo

Yoshimura, Yuka

Murakami, Ami

Saito, Yua

Kusunoki, Toshie

Samune, Yoshihiro

Nakayama, Emi E.

Miyazaki, Kazuo

Shioda, Tatsuo
Funding

Funding for this research was provided by:

the Japan Agency for Medical Research and Development (JP20he0822004)
License Information

Text and Data Mining valid from 2022-09-16

Version of Record valid from 2022-09-16
More Information

Article History

Received: 3 May 2022

Accepted: 7 September 2022

First Online: 16 September 2022

Change Date: 20 January 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s41598-023-28371-z

Competing interests

: The authors declare no competing interests.

Updates are available Correction dated 2023-01-20

Click to view Correction: https://doi.org/10.1038/s41598-023-28371-z